Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
9.24
+0.08 (0.87%)
At close: May 13, 2026, 4:00 PM EDT
9.25
+0.01 (0.11%)
Pre-market: May 14, 2026, 8:53 AM EDT
Ocular Therapeutix Revenue
Ocular Therapeutix had revenue of $10.79M in the quarter ending March 31, 2026, with 0.81% growth. This brings the company's revenue in the last twelve months to $52.04M, down -12.76% year-over-year. In the year 2025, Ocular Therapeutix had annual revenue of $51.95M, down -18.47%.
Revenue (ttm)
$52.04M
Revenue Growth
-12.76%
P/S Ratio
38.88
Revenue / Employee
$160,117
Employees
325
Market Cap
2.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 51.95M | -11.77M | -18.47% |
| Dec 31, 2024 | 63.72M | 5.28M | 9.03% |
| Dec 31, 2023 | 58.44M | 6.95M | 13.49% |
| Dec 31, 2022 | 51.49M | 7.97M | 18.32% |
| Dec 31, 2021 | 43.52M | 26.12M | 150.08% |
| Dec 31, 2020 | 17.40M | 13.18M | 311.71% |
| Dec 31, 2019 | 4.23M | 2.24M | 112.41% |
| Dec 31, 2018 | 1.99M | 67.00K | 3.48% |
| Dec 31, 2017 | 1.92M | 36.00K | 1.91% |
| Dec 31, 2016 | 1.89M | 137.00K | 7.83% |
| Dec 31, 2015 | 1.75M | 978.00K | 126.68% |
| Dec 31, 2014 | 772.00K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 10.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.18B |
| ADMA Biologics | 509.86M |
| Aurinia Pharmaceuticals | 298.30M |
| Ascentage Pharma Group International | 82.08M |
| Intellia Therapeutics | 66.09M |
| Stoke Therapeutics | 32.08M |
| Generate Biomedicines | 30.30M |
| Taysha Gene Therapies | 7.47M |
OCUL News
- 1 day ago - Ocular Therapeutix Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 5 days ago - Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Ocular Therapeutix Earnings Call Transcript: Q1 2026 - Transcripts
- 9 days ago - Ocular Therapeutix reports Q1 EPS (40c), consensus (31c) - TheFly
- 9 days ago - Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights - GlobeNewsWire
- 15 days ago - Ocular Therapeutix enrolls first patient in Axpali trial - TheFly
- 15 days ago - Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD - GlobeNewsWire
- 16 days ago - Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026 - GlobeNewsWire